Natalizumab induction and maintenance therapy for Crohn's disease.

By W. Sandborn, J. Colombel, R. Enns, B. Feagan, S. Hanauer, I. Lawrance, R. Panaccione, M. Sanders, Stefan Schreiber, S. Targan and 5 more. New England Journal of Medicine, 2005

922 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. (2010, background): “5) were allocated to receive infusions of placebo or 300 mg of natalizumab every 4 weeks for 12 months.[79] Maintenance natalizumab resulted in higher rates of sustained response (61%vs 28%,pb0.”
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease (2016, background): “Therapies targeting α L (efalizumab) and α 4 (natalizumab) demonstrated potential in Crohn’s disease 35,36 , but both medications have been associated with progressive multifocal leukoencephalopathy (PML) 37 .”
Mucosal healing in inflammatory bowel diseases: a systematic review (2012, background): “Endoscopy at 3 months might therefore be used to predict responders to infliximab for maintenance therapy in active luminal CD.113 With regard to adalimumab the EXTEND trial evaluated adalimumab 160/80 mg at weeks 0/2 and maintenance 40 mg every other week for induction and maintenance of mucosal he”
Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices (2008, methodology): “Recently, CRP has been used in several randomized controlled trials of biologic agents in CD (44, 45).”